Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

333 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Inhibition of the myeloperoxidase chlorinating activity by non-steroidal anti-inflammatory drugs: flufenamic acid and its 5-chloro-derivative directly interact with a recombinant human myeloperoxidase to inhibit the synthesis of hypochlorous acid.
Van Antwerpen P, Dufrasne F, Lequeux M, Boudjeltia KZ, Lessgyer I, Babar S, Moreau P, Moguilevsky N, Vanhaeverbeek M, Ducobu J, Nève J. Van Antwerpen P, et al. Among authors: neve j. Eur J Pharmacol. 2007 Sep 10;570(1-3):235-43. doi: 10.1016/j.ejphar.2007.05.057. Epub 2007 Jun 12. Eur J Pharmacol. 2007. PMID: 17610876
Probucol does not inhibit myeloperoxidase-dependent low-density lipoprotein oxidation as a potent protective effect in atherosclerosis.
Van Antwerpen P, Néve J, Moreau P, Boudjeltia KZ, Vanhaeverbeek M, Prévost M, Babar S, Legssyer I, Moguilevsky N, Ducobu J. Van Antwerpen P, et al. Among authors: neve j. J Cardiovasc Pharmacol. 2007 Sep;50(3):350-1. doi: 10.1097/FJC.0b013e31809501dc. J Cardiovasc Pharmacol. 2007. PMID: 17878766 No abstract available.
Impact of myeloperoxidase-LDL interactions on enzyme activity and subsequent posttranslational oxidative modifications of apoB-100.
Delporte C, Boudjeltia KZ, Noyon C, Furtmüller PG, Nuyens V, Slomianny MC, Madhoun P, Desmet JM, Raynal P, Dufour D, Koyani CN, Reyé F, Rousseau A, Vanhaeverbeek M, Ducobu J, Michalski JC, Nève J, Vanhamme L, Obinger C, Malle E, Van Antwerpen P. Delporte C, et al. Among authors: neve j. J Lipid Res. 2014 Apr;55(4):747-57. doi: 10.1194/jlr.M047449. Epub 2014 Feb 17. J Lipid Res. 2014. PMID: 24534704 Free PMC article.
Captopril inhibits the oxidative modification of apolipoprotein B-100 caused by myeloperoxydase in a comparative in vitro assay of angiotensin converting enzyme inhibitors.
Van Antwerpen P, Legssyer I, Zouaoui Boudjeltia K, Babar S, Moreau P, Moguilevsky N, Vanhaeverbeek M, Ducobu J, Nève J. Van Antwerpen P, et al. Among authors: neve j. Eur J Pharmacol. 2006 May 10;537(1-3):31-6. doi: 10.1016/j.ejphar.2006.03.022. Epub 2006 Mar 20. Eur J Pharmacol. 2006. PMID: 16631159
Inhibition of myeloperoxidase activity by the alkaloids of Peganum harmala L. (Zygophyllaceae).
Bensalem S, Soubhye J, Aldib I, Bournine L, Nguyen AT, Vanhaeverbeek M, Rousseau A, Boudjeltia KZ, Sarakbi A, Kauffmann JM, Nève J, Prévost M, Stévigny C, Maiza-Benabdesselam F, Bedjou F, Van Antwerpen P, Duez P. Bensalem S, et al. Among authors: neve j. J Ethnopharmacol. 2014 Jun 11;154(2):361-9. doi: 10.1016/j.jep.2014.03.070. Epub 2014 Apr 16. J Ethnopharmacol. 2014. PMID: 24746482
333 results